Telitacicept Explained

Tradename:Tai'ai
Routes Of Administration:Injection
Legal Status:Rx in China
Cas Number:2136630-26-5
Unii:1FHM3D7Z49
Synonyms:RC18

Telitacicept (trade name Tai'ai) is a pharmaceutical drug used for the treatment of systemic lupus erythematosus (SLE).[1]  It is being developed by Yantai Rongchang Pharmaceuticals and RemeGen for various autoimmune diseases.[2] In 2021, telitacicept was approved in China for the treatment of patients with active SLE.[3]  It is also being studied for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS).[3]

Telitacicept is a fusion protein that combines a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and a fragment of human immunoglobulin G (IgG).[3]

Notes and References

  1. Fan Y, Gao D, Zhang Z . Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus . Drugs of Today . 58 . 1 . 23–32 . January 2022 . 35107091 . 10.1358/dot.2022.58.1.3352743 . 246405604 .
  2. Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y . Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease . Immunopharmacology and Immunotoxicology . 43 . 6 . 666–673 . December 2021 . 34519594 . 10.1080/08923973.2021.1973493 . 237504252 .
  3. Dhillon S . Telitacicept: First Approval . Drugs . 81 . 14 . 1671–1675 . September 2021 . 34463932 . 10.1007/s40265-021-01591-1 . 237357826 .